	US 12,383,604 B2
	Bioengineering tertiary lymphoid structures using chitosan-based hydrogels
James Mulé, Odessa, FL (US); Rana Falahat, Tampa, FL (US); and Genyuan Zhu, Columbia, SC (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Appl. No. 17/052,973
Filed by H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
PCT Filed May 8, 2019, PCT No. PCT/US2019/031306 § 371(c)(1), (2) Date Nov. 4, 2020, PCT Pub. No. WO2019/217547, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/668,609, filed on May 8, 2018.
Prior Publication US 2021/0220441 A1, Jul. 22, 2021
Int. Cl. A61K 38/19 (2006.01); A61K 9/00 (2006.01); A61K 35/26 (2015.01); A61K 47/36 (2006.01)

CPC A61K 38/195 (2013.01) [A61K 9/0024 (2013.01); A61K 35/26 (2013.01); A61K 38/191 (2013.01); A61K 47/36 (2013.01)]

8 Claims

1. A composition consisting of CCL19, CCL21, CXCL13, and lymphotoxin-alpha2/beta1 encapsulated in lipid-enveloped mesoporous microparticles embedded in a thermosensitive chitosan hydrogel.